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Abstract 
 
Mitogen-activated protein kinases (MAPK) allow a cell to respond to external signals to 
grow, divide or undergo apoptosis.  One example is the c-Jun N-terminal kinase 2 (JNK2). This 
protein is unique in that it can autophosphorylate, or phosphorylate itself. It was found that these 
proteins tend to form aggregates of four, or tetramers, when inactive and remain as single units, 
or monomers, when active. In glioblastoma and lung carcinoma cells, JNK2s are reported to be 
constitutively, or always, active. This study aimed to investigate a selection of JNK2 mutations 
determine which of these mutations can alter JNK2 activity and oligomerization state.  
Results from size-exclusion chromatography and light scattering analysis (SEC-LS) 
suggested that while the wild type JNK2 exists as a mixture of monomers and tetramers, the 
activation loop chimera mutant (C177G/N179S) exists only as monomers.  Additionally, 
phosphorylation assay analysis showed increased autophosphorylation activity of the activation 
loop chimera mutant compared to the wild type.  These results suggest that the activation loop 
may be involved in the mechanism of JNK2 regulation.  Elucidation of MAPK regulation 
mechanisms may allow more effective cancer therapy screening and increase overall 
understanding of tumor growth mechanisms. 
 
 
Background: 
 
Kinases are proteins that add phosphate groups to other proteins, a process known as 
phosphorylation.  In general, these proteins serve to transmit signals from the outside of a cell to 
the inside, a process known as signal transduction. As phosphate groups are transferred, proteins 
are either activated or inactivated, resulting in some change in cellular activity. A signaling 
pathway consists of a group of interacting proteins that link a stimulus to the response.   
One important signaling pathway in cancer research is the MAPK pathway. This pathway 
contains a variety of proteins, including a group of kinases called mitogen-activated protein 
kinases (MAPKs). Normally, this pathway links mitogenic signals (signals to divide) and stress 
signals to alter transcription of certain genes. Cells then assemble molecular machinery to initiate 
mitosis or programmed cell death. However, studies have shown that in some cancer cells, 
certain MAPKs behave abnormally, resulting in uncontrolled cell division.1   
One important MAPK is the c-Jun N-terminal kinase (JNK).  There are three known 
JNKs: JNK1, JNK2 and JNK3. These kinases are activated by mitogen activated kinase kinase 4 
and 7 (MKK4 and MKK7). However, JNK2 is unique in its ability to autophosphorylate, or 
phosphorylate itself.  When JNK2 is doubly phosphorylated by upstream kinases or by 
autophosphorylation, it becomes active and phosphorylates Activating Transcription Factor 2 
(ATF2) and various other proteins.1 However, in glioblastoma and lung carcinoma cells, JNK2 is 
found to be constitutively, or always, active. Recent findings have shown that JNK2 can 
oligomerize (form aggregates) with itself to regulate its activity.2  Wild-type JNK2 was found as 
a mixture of monomers, dimers, and tetramers in solution. However, an F170R mutation resulted 
in inhibition of autophosphorylation activity and stabilization of its tetramer form.2 Therefore, 
JNK2 activity may depend on whether the protein is predominately in its monomer or tetramer 
state.  A model of JNK2 regulation is shown in Figure 1. This study aimed to investigate a 
selection of somatic mutations (mutations that occur in somatic cancer cells) of JNK2. Each 
mutant was cloned, expressed, purified and tested for activity and oligomerization state. The 
results may provide insight on therapeutic approaches of inhibiting JNK2 activity and thereby 
halting tumor growth. 
 
 
 
 
Figure 1: A proposed model of JNK2 regulation. 
 
 
Materials and Methods: 
 
The protocol for this experiment can be separated into three parts: preparation of 
phosphate-free JNK2, light scattering analysis, and JNK2 phosphorylation assay analysis. 
 
Preparation of Phosphate-free JNK2 
 
 The mutations chosen for investigation were selected from the Catalogue of Somatic 
Mutations in Cancer (COSMIC) database.  Specifically, mutations near the activation loop of 
JNK2 were chosen. Additionally, an activation loop chimera DNA was prepared according to the 
protocol in Cui, et. al.3 The sequences of JNK1 and JNK2 were aligned and differences in the 
activation loop were mutated onto the JNK2 sequence (C177G/N179S). The full list of mutations 
chosen are as follows: F170R, A176V, M181I, A193V, E204K, V206L, and activation loop 
chimera (C177G/N179S). Overlap extension polymerase chain reaction (PCR) was used to 
produce the mutant jnk2 constructs. The products of the first round of PCR was run on a 10% 
agarose gel, excised, and purified. For each mutant, the two products from the first round were 
then mixed for the second round of PCR, resulting in the complete, amplified product. This 
product was then ligated into a Qiagen pET28a(+) vector using NheI and HindIII restriction sites. 
This vector contained the gene for JNK2 with an N-terminal His-tag cleavable by thrombin. 
Further details of this construct are described in Madsen et al.4  
The cloning and purification protocol was followed largely according to Zhan, et. al.6 E. 
coli strain BL21 (DE3) was electroporated to enhance DNA uptake as described in House et al.5 
Each jnk2 construct was co-transferred with  pCDF-Duet λ-phosphatase into the E. coli. Then, a 
single colony was mixed with 30 mL of  Luria-Broth (LB) media with 30 µg/mL Kanamycin and 
5 µg/mL Spectinomycin grown overnight at 37 ℃. After overnight growth, the cells were then 
diluted 100X with LB containing 30 µg/mL Kanamycin and 5 µg/mL Spectinomycin. This 
diluted culture was grown at 37 ℃ until O.D600 reached 0.6.  The cells were then induced with 
IPTG and cultured at 30 ℃  for 3 hours. The cells were then centrifuged at 7000g for 12 minutes, 
frozen in liquid nitrogen, and stored at -80 ℃. 
To purify the expressed protein, the cells were first lysed in buffer A containing 1% 
Triton X-100 and 0.5 M NaCl (see supplement for buffer details). The lysate was then sonicated 
with 5 second pulses for 15 minutes at 4 ℃. Temperature was monitored using a thermometer 
and pulses were regulated to keep the lysate under 10 ℃. Then, the lysate  were centrifuged for 
30 minutes at 16000 rpm. The supernatant was incubated with Ni-NTA beads for 1 hour at 4 ℃ 
with a standard 3-D laboratory shaker., and the supernatant was incubated with Ni-NTA beads. 
The beads were then poured into a 98 mL Econo-Column (by Bio-Rad). The beads were first 
washed with buffer A containing 10 mM imidazole and eluted with imidazole. Then, the JNK2 
was eluted with 25 mL of buffer A containing 200 mM imidazole at pH 8. The elution product 
was then poured into a Mono Q HR 10/10  anion exchange column (from General Electric). 
After equilibration in buffer B, the protein was fractionated over 15 column volumes with a 
gradual increase in NaCl concentration from 0 to 0.5 M.  Fractions corresponding to the largest 
chromatographic peak were combined and dialyzed in buffer C containing 10% glycerol.  After 
dialysis, concentration was measured using standard Bradford assay techniques and a 
predetermined JNK2 calibration curve. If the concentration was too low, the sample was 
concentrated by centrifuging it in an Amicon Ultra-15 concentrator for about 10 minutes at 4400 
rpm. The dialyzed samples were freezed in liquid nitrogen.  Purity of each fraction was assessed 
by 12% SDS/PAGE gel.  A western blot analysis was also carried out on each fraction to assess 
if any JNK2 remained phosphorylated. Exact buffer concentrations and components are listed in 
the supplement, which derive from the protocol in Zhan, et. al.6 
 
Light Scattering 
 
All buffers and solutions were first filtered through an Anodisc 0.02 µm filter prior to 
light scattering analysis. 
Bovine serum albumin was first injected into a Wyatt DAWN Heleos instrument to 
normalize the detectors. Between the pump and the QELS detectors, a TSK-GEL G 3000PWXL 
column (by Tosoh Bioscience LLC) allowed separation of any oligomers prior to reaching the 
detector. The size-exclusion chromatography was performed with buffer F at a flow rate of 0.4 
mL/min at 25 ℃. Prior to light scattering analysis, each JNK2 protein was first dialyzed in buffer 
F. The concentrations of the dialyzed samples were measured using a standard Bradford assay 
technique with a predetermined calibration curve. Then, each sample was diluted to 25 µM with 
buffer F, with a final volume of 100 µL. The samples were then centrifuged at 13400 rpm for 30 
seconds to precipitate any insoluble material that may produce artifacts during light scattering 
analysis. 20 µL of each sample was injected into the Heleos instrument.  Molar masses were 
calculated using Astra software (by Wyatt Technology). Specific details of the process are 
described in Kaoud, et al.7 
 
 
JNK2 Phosphorylation Assay 
 
To estimate the kinase activity of different JNK2 fractions, JNK2 kinase assays were 
conducted.   The assays were performed on a standard 96-well plate with 300 µL capacity per 
well.  Out of all the JNK2 variants purified, 2 were analyzed for the sake of time: wild-type and 
C177G/N179S. For each variant, 250 nM of the JNK2 was mixed with either 25 nM activated 
MKK4, 25 nM activated MKK7, 25 nM of both MKK4 and MKK7 or no MKK at all.  Each well 
also contained 11 mM MgCl2, 2 mM DTT, 10 μg/ml BSA, 50 mM KCl, 0.1 mM EDTA, 0.1 
mM EGTA in 25 mM HEPES buffer-pH 7.5.  The reaction was initiated with addition of 1 mM 
ATP and incubation at 25 ℃ for 16 minutes. Then, a 5 µL aliquot from each well was transferred 
to another set of wells containing 12.5 uM of ATF-2 and buffer F.  The reactions were then 
quenched using buffer D. The quenched samples were then run on a 12% SDS/PAGE gel. 
Nitrocellulose membranes were prepared by immersing them in methanol, water, then buffer E 
for 5 minutes each. The proteins were transferred onto the nitrocellulose membranes using a wet 
blotting system (from Bio-Rad) at 30 V in buffer E for 2 hours.  
After transfer, the membranes were briefly washed with methanol, water and then 
phosphate buffered saline (PBS) for 5 minutes each. The membranes were incubated in LI-COR 
Odyssey Blocking Buffer for 30 minutes while gently shaking. A primary antibody solution 
containing 1:5000 anti-phospho-Threonine-Proline (p-Thr-Pro-101) mouse mAb (Cell Signaling 
Technology) and 1:2000 anti-phospho-Tyrosine (p-Tyr-1000) rabbit mAb (Cell Signaling 
Technology) in LI-COR Odyssey blocking buffer. After blocking, the 5 mL of the antibody 
solution was poured over each membrane and incubated for 1 hour. The membranes were then 
washed with Tris-buffered saline with Tween 20 (TBST). A mixture of secondary antibodies 
with two different dyes (LI-COR® IRDye 800CW GT anti-rabbit and LI-COR® IRDye 680RD 
Goat anti-mouse secondary antibodies) was then poured over the membranes and incubated for 1 
hour. The membranes were washed with TBST and imaged using the LI-COR imaging system. 
 
 
 
 
 
 
 
 
 
 
 
 
Results  
 
Preparation of Phosphate-free JNK2 
 
The use of a lambda phosphatase co-expression protocol enabled the purification of 
phosphate-free JNK2. Using this form of JNK2, we could monitor its autophosphorylation and 
relate it to its activity against the downstream substrate, ATF-2. A sample chromatogram 
produced from the purifications is shown in Figure 2. Each pooled fraction was run on a 12% 
SDS/PAGE gel, which is shown in Figure 3. A strong single band at around 50 kDa in each lane 
indicated presence of relatively pure JNK2 in each fraction. Western blot analysis was performed 
to assess phosphorylation status of the JNK2 in each pooled fraction. These western blots are 
shown in Figure 4. The absence of phosphorylation signal despite presence of total JNK2 
indicated that each fraction contained phosphate-free JNK2.  
 
 
 
Figure 2: This chromatogram was produced from the purification of JNK2 F170R. Similar chromatograms 
were produced for the other JNK2 variants purified. The blue line represents UV signal in each fraction 
and the green line represents increasing salt concentration of buffer B. 
 from 0 to 0.5 M NaCl. 
 
 
 
 
Figure 3: This figure shows the purified JNK2 samples ran on a 12% SDS/PAGE gel. Parts of the gel in (a) 
and (b) have been omitted as they contained proteins not relevant to this study. The fractions are 
labeled as follows: 1 = Ladder = JNK2 F170R, 2 = F170R, 3 = Wild type - fraction 2, 4 = wild type fraction 
1, 5 = ladder, 6 = activation chimera loop – fraction 2, 7 = activation loop chimera (C177G/N179S) – 
fraction 1, 8 = ladder, 9 = A176V – fraction 1, 10 = A176V – fraction 2, 11 = M181I – fraction 1, 12 = 
M181I – fraction 2, 13 = A193V, 14 = E204K – fraction 1, 15 = E204K – fraction 2, 16 = V206I – fraction 1, 
17 = V206I – fraction 2.  This image was taken with a LI-COR Odyssey imager. 
 
 
 
 Figure 4: This figure shows the Western Blots of each sample created after the purification step.  The 
proteins are labeled as follows: Act = active JNK2 control, WT-1 = wild type- fraction 1, WT-2 = wild type 
- fraction 2, Act1 = activation loop chimera (C177G/N179S) – fraction 1, Act2 = activation loop chimera – 
fraction 2,  A1 = A176V – fraction 1, A2 = A176V – fraction 2, B1 = M181I – fraction 1, B2 = M181I – 
fraction 2, C = A193V, E1 = E204K – fraction 1, E2 = E204K – fraction 2, F1 = V206I – fraction 1, F2 = V206I 
– fraction 2. This image was taken using a LI-COR Odyssey imager. 
 
 
Light Scattering 
 
The light scattering analysis (Figure 6) showed that the wild type formed a mixture of 
monomers (50 kDa) and tetramers (200 kDa) in solution.  Meanwhile, the activation loop 
chimera remained as monomers (50 kDa), whether at a moderate concentration of 25 µM or a 
high concentration of 100 µM. 
 
 
Figure 6: This figure shows the light scattering result for the JNK2 wild type and activation loop chimera 
(C177G/N179S). The curve lines represent differential refractive index (dRI) signals, while the cluster of 
dots represent the calculated molar mass within the sample.  The wild type enzyme is represented in 
blue, while the activation loop chimera at 25 µM and 100 µM are represented in red and black, 
respectively.  
 
JNK2 Phosphorylation Assay 
 
The results of the Western Blot analysis on the JNK2 phosphorylation assay are shown in Figure 
5. The activation loop chimera (C177G/N179S) mutant (Figure 5b) had a greater 
autophosphorylation activity than the wild type (Figure 5a) at both thr-183 and tyr-185. 
 
 
 
Figure 5: This figure shows the results of the JNK2 phosphorylation assay. The wild type protein is shown 
in (a) while the activation loop chimera (C177G/N179S) is shown in (b). The pp-JNK2 row shows the 
amount of double phosphorylated JNK2, while the p-thr and p-tyr rows show the amount of 
phosphorylation at thr-183 and tyr-185, respectively. Images were taken using a LI-COR imager. 
 
 
Discussion  
 
 It had been previously demonstrated that JNK2 can potentially regulate its activity 
through oligomerization.2 Specifically, it was found that an inactive form, JNK2 F170R, formed 
exclusively tetramers. Therefore, mutations within the tetramer interface may disrupt the JNK2 
tetramer into monomeric units, possibly increasing autophosphorylation and downstream 
activity. We first investigated several JNK2 mutants to find a mutation that would disrupt the 
tetramer. Then we assessed autophosphorylation activity of each mutant. However, to accurately 
measure autophosphorylation activity, preparation of phosphate-free JNK2 was essential. Since 
JNK2 autophosphorylates in bacterial cells, we co-expressed JNK2 with λ-phosphatase. As 
demonstrated by the high purity of the protein bands in Figure 3, the purification protocol 
appeared to be an effective method to isolate JNK2 from the co-expressed λ-phosphatase. 
Additionally, as shown in Figure 4, the lack of pp-JNK signal despite presence of JNK2 
demonstrates the effectiveness of co-expressing λ-phosphatase to produce phosphate-free JNK2.  
 Light scattering analysis uses the principles of Brownian motion to determine the size of 
particles, such as proteins, in solution. When light is shined into a sample and scattered, random 
particle motion results in temporal fluctuations of the scattered light intensity. Heavier particles 
tend to move slower, resulting in slower fluctuations. With proper calibration, these fluctuations 
can be converted into the molar mass of the particles in solution. We used light scattering 
analysis to calculate the molar mass of particles for each JNK2 mutant and determine the 
respective oligomerization states. Figure 6 showed that the wild type formed a mixture of 
monomers (50 kDa) and tetramers (200 kDa) in solution.  However, the activation loop chimera 
remained as monomers (50 kDa), whether at a moderate concentration of 25 µM or a high 
concentration of 100 µM. Therefore, it is possible that the C177G/N179S mutations may lie 
within the binding interface, resulting in disruption of the tetramer into monomers.  
To determine if tetramer disruption and monomer prevalence correlated with 
autophosphorylation activity, we performed a phosphorylation assay on the two JNK variants. 
The phosphorylation assay indicated that the activation loop chimera (C177G/N179S) mutant 
(Figure 5b) has a greater autophosphorylation activity than the wild type (Figure 5a).  
Therefore, disruption of the tetramer into monomers resulted in increased activity of JNK2. 
These results complement a previous study which found that the JNK2 F170R mutant formed 
exclusively tetramers and exhibited inhibition of its autophosphorylation activity.2  
 If more time was allotted, we would have conducted the light scattering analysis and 
phosphorylation assay with other JNK2 mutants to further elucidate which somatic mutations can 
lead to altered JNK2 activity and oligomerization states.  Additionally, we would have 
performed crystallography on the activation loop chimera, JNK2 F170R mutant and wild type to 
locate the binding interface and corroborate the findings with current data. 
Overall, this study has helped elucidate a possible element of JNK2 regulation. 
Elucidation of MAPK regulation mechanisms may allow more effective cancer therapy 
screening and increase overall understanding of tumor growth mechanisms.  
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Supplementary Information 
Buffer Legend 
 
Note: Buffers A-C were used according to the protocol in Zhan, et al.6 Buffer F was used 
according to the protocol in Kaoud, et al.7 
 
Buffer A (pH 8) 
20 mM Tris-HCl 
0.03% Brij-30 
0.1% (v/v) β-mercaptoethanol 
5 mM imidazole 
1 mM benzamidine 
0.1 mM PMSF 
0.1 mM TPCK 
 
Buffer B 
 20 mM Tris-HCl 
0.03% (v/v) Brij-30 
0.1% (v/v) β-mercaptoethanol 
 
Buffer C 
 25 mM HEPES 
50 mM KCl 
0.1 mM EDTA 
0.1 mM EGTA 
2 mM DTT 
 
Buffer D (quenching buffer) 
 20 mM HEPES 
 200 mM KCl 
 0.1% BSA 
 50 mM EDTA 
 1 mM EGTA 
 
Buffer E (transfer buffer) 
25 mM Tris 
192 mM glycine 
20% methanol 
  
Buffer F 
 25 mM HEPES (pH 7.5) 
100 mM KCl 
0.1 mM EDTA 
1 mM DTT 
  
  
 
